外周动脉疾病随机临床试验中的种族与民族代表性
本文综述了外周动脉疾病(PAD)随机临床试验中少数族裔代表性不足的现状与原因。黑人、西班牙裔及女性入组率持续偏低,而黑人美国人PAD患病率更高且临床结局相对更差。参与者意愿与信任、经济负担、文化障碍、健康素养不足及试验地点交通障碍等因素影响代表性,申办方的成本收益假设与经费来源亦影响种族报告。作者认为需切实努力确保少数族裔在PAD临床试验中的充分代表性。
要点
- 黑人、西班牙裔美国人及女性在PAD临床试验中入组率持续偏低。
- 黑人美国人PAD患病率更高且临床结局相对更差。
- 少数族裔参与意愿不低,但经济负担、文化障碍与健康素养不足阻碍其入组。
核心结论
- 需切实努力确保少数族裔在PAD临床试验中的充分代表性,以开发更持久有效且符合真实世界人群需求的PAD治疗。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 黑人美国人PAD患病率更高,临床结局相对非西班牙裔白人 Americans 更差。
- 黑人、西班牙裔美国人及女性在临床试验中的入组率持续偏低。
- 少数族裔参与临床试验的意愿与非西班牙裔白人相当。
- 经济负担、文化障碍、健康素养与教育不足可能阻碍少数族裔参与临床试验和获得医疗照护。
- 临床试验入组地点常构成交通障碍,对建立多样化研究人群产生负面影响。
关键数值与推荐
- 原文未报告具体标准与数值。
临床怎么用
- 作者认为需切实努力确保少数族裔在PAD临床试验中的充分代表性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trial enrollment provides various benefits to study participants including early access to novel therapies that may potentially alter the trajectory of disease states. Trial sponsors benefit from enrolling demographically diverse trial participants enabling the trial outcomes to be generalizable to a larger proportion of the community at large. Despite these and other well-documented benefits, clinical trial enrollment for Black and Hispanic Americans as well as women continues to be low. Specific disease states such as peripheral artery disease (PAD) have a higher prevalence and clinical outcomes are relatively worse in Black Americans compared with non-Hispanic white Americans. The recruitment process for PAD clinical trials can be costly and challenging and usually comes at the expense of representation. Participant willingness and trust, engagement, and socioeconomic status play essential roles in the representation of under-represented minority (URM) groups. Despite the contrary belief, URM groups such as Blacks and Hispanics are just as willing to participate in a clinical trial as non-Hispanic Whites. However, financial burdens, cultural barriers, and inadequate health literacy and education may impede URMs' access to clinical trials and medical care. Clinical trials' enrollment sites often pose transportation barriers and challenges that negatively impact creating a diverse study population. Lack of diversity among a trial population can stem from the stakeholder level, where corporate sponsors of academic readers do not consider diversity in clinical trials a priority due to false cost-benefit assumptions. The funding source may also impact the racial reporting or the results of a given trial. Industry-based trials have always been criticized for over-representing non-Hispanic White populations, driven by the desire to reach high completion rates with minimum financial burdens. Real efforts are warranted to ensure adequate minorities' representation in the PAD clinical trials and to the process toward the ultimate goal of developing more durable and effective PAD treatments that fit the needs of real-world populations.
引用
- Alnahhal KI, Wynn S, Gouthier Z, et al. Racial and ethnic representation in peripheral artery disease randomized clinical trials. Ann Vasc Surg. 2024. PMID: 39009128. doi:10.1016/j.avsg.2024.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。